CN Patent

CN106661030A — 用于药物制剂中的PI3K δ选择性抑制剂的改良形式

Assigned to Rhizen Pharmaceuticals AG · Expires 2017-05-10 · 9y expired

What this patent protects

本发明涉及选择性PI3K δ抑制剂(S)‑2‑(1‑(4‑氨基‑3‑(3‑氟‑4‑异丙氧基苯基)‑1H‑吡唑并[3，4‑d]嘧啶‑1‑基)乙基)‑3‑(3‑氟苯基)‑4H‑色烯‑4‑酮(TGR‑1202)的对甲苯磺酸盐(PTSA)的固态形式。本发明还涉及制备所述盐的方法，含有所述盐的药物组合物，及通过施用所述盐治疗PI3K激酶介导的疾病或病症，如癌症的方法。

USPTO Abstract

本发明涉及选择性PI3K δ抑制剂(S)‑2‑(1‑(4‑氨基‑3‑(3‑氟‑4‑异丙氧基苯基)‑1H‑吡唑并[3，4‑d]嘧啶‑1‑基)乙基)‑3‑(3‑氟苯基)‑4H‑色烯‑4‑酮(TGR‑1202)的对甲苯磺酸盐(PTSA)的固态形式。本发明还涉及制备所述盐的方法，含有所述盐的药物组合物，及通过施用所述盐治疗PI3K激酶介导的疾病或病症，如癌症的方法。

Drugs covered by this patent

umbralisib-tosylate (UMBRALISIB TOSYLATE)

Patent Metadata

Patent number: CN106661030A
Jurisdiction: CN
Classification: —
Expires: 2017-05-10
Drug substance claim: No
Drug product claim: No
Assignee: Rhizen Pharmaceuticals AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.